NEW YORK – OneOncology and Genentech on Monday announced that they have entered into a strategic collaboration to bring comprehensive genomic profiling to the community oncology setting. Genentech also said that it would be launching a new basket trial enrolling patients treated throughout the OneOncology Research Network (OneR).
Genentech's basket trial, dubbed Targeting Actionable Mutation Study in Cancer (MyTACTIC), will be the first clinical trial available to patients within OneR. Through the Phase II trial, Genentech plans to match patients with metastatic solid cancers to investigational therapies on the basis of comprehensive genomic profiling results, and to evaluate the percentage of patients with a confirmed overall response to treatment as the study's primary endpoint. Patients treated within OneOncology's network will make up part — though not all — of the roughly 200 patients Genentech plans to enroll in MyTACTIC; the company will also be working with other community oncology practices across the country.
Genentech and OneOncology's partnership will also extend beyond the scope of the MyTACTIC basket trial. Genentech will be working with the network of over 400 providers from 175 sites on clinical trials, scientific research, and real-world data studies with the goal of improving access to comprehensive genomic profiling and clinical trials in the community setting, and in turn improving treatment options for patients.
As an element of the partnership, OneOncology and Genentech will also form a committee to design both interventional and non-interventional clinical trials meant to assess the impact of precision medicine on patient outcomes as well as the larger healthcare system. The committee will focus, for instance, on generating real-world evidence pertaining to how comprehensive genomic profiling is integrated and used in clinical practice, establishing research sites, and identifying patients for enrollment in clinical trials across OneR.
"We are excited to collaborate with OneOncology to bring state-of-the-art cancer care to community oncology practices, where the diverse patient population creates a greater opportunity to advance inclusive research," Jamie Freedman, Genentech's US head of medical affairs said in a statement. "The pandemic dramatically highlights the need to rethink how healthcare is delivered, and our goal is to enable a deeper understanding of each individual patient's journey and to deliver the highest quality of research and evidence-based care."
In August, Foundation Medicine — which, like Genentech, is a subsidiary of Roche — also inked a partnership with OneOncology focused on improving access to genomic profiling and personalized medicine in community oncology practices across the US. Â